Key Points for Decision Makers {#FPar1}
==============================

Chemotherapy and associated costs were identified as major cost components in several publications; costs related to screening methods and administering screening were also high.Treatment costs represented a significant proportion of direct costs, specifically small cell lung cancer (SCLC) medication costs or surgical costs, which included high associated costs from hospitalisation, nurse visits, emergency room visits, follow-up appointments and outpatient care.Only limited information on the indirect costs of SCLC is available in the published literature (namely, data on productivity loss due to premature death).The varied nature of the studies captured indicates that a more uniform and consistent approach is needed when reporting on the costs of SCLC.

Introduction {#Sec1}
============

Lung cancer is the second most prevalent cancer worldwide, with more than one quarter (27%) of all cancer deaths in 2015 attributed to lung cancer \[[@CR1]\]. It is a leading cause of cancer mortality, responsible for 1.69 million deaths worldwide in 2015 \[[@CR2]\]. As the symptoms associated with lung cancer are often non-specific, it is frequently diagnosed in the late stages; this is reflected in a 5-year survival rate estimated at \<20% \[[@CR3]\].

SCLC accounts for approximately 15% of all lung cancers and has its highest occurrence in smokers \[[@CR4]\]. While representing a comparatively small proportion of lung cancers, SCLC is the most aggressive from of lung cancer, with faster growth and earlier metastasis than any other pulmonary cancer \[[@CR5]\]. It is characterised by a rapid doubling time and early onset of dissemination \[[@CR5]\]. Although SCLC is initially sensitive to existing forms of chemotherapy, progression occurs rapidly and a high incidence of recurrence has been observed \[[@CR4], [@CR6]\]. Surgical resection is the mainstay of treatment for patients with non-small cell lung cancer (NSCLC), however nearly 70% of patients present with metastatic or locally advanced disease \[[@CR7]\]. Compared with NSCLC, curative surgery is rarely an option in SCLC as most patients present with already widely metastatic or locally advanced disease at diagnosis. Untreated patients typically have a median lifespan of 2--4 months following diagnosis \[[@CR8]\].

The limited rate of early diagnosis, rapid development of resistance to existing treatment, and low 5-year survival rates present a significant unmet need in the disease area \[[@CR6]\]. Although SCLC is only a small subset of total lung cancers, it is still a considerable social, economic and humanistic burden, with close to 30,000 new cases being reported in the US annually \[[@CR6], [@CR8]\].

The overarching objective of this systematic literature review (SLR) was to conduct a comprehensive search to synthesise the direct and indirect costs associated with SCLC in Australia, Brazil, Canada, Europe, Japan, Russia and the US. The authors deemed these populous regions to represent various levels of socioeconomic development, across five continents.

Key components and drivers of the economic burden of SCLC were examined across different SCLC patient subpopulations. Economic burden was defined as any direct and indirect costs of SCLC, including diagnosis and treatment costs, loss of work productivity, or costs to caregivers or family members.

Methodology {#Sec2}
===========

The primary objective of this literature review was to summarise the economic burden of SCLC and to define and understand the key drivers and factors that underpin these impacts. These included social costs (e.g. lost productivity, caregiver burden, absenteeism, presenteeism, out-of-pocket expenses, burden of premature mortality) and healthcare costs (e.g. direct medication costs, primary care costs and secondary care costs, such as hospital admissions). The secondary objectives were to understand how the cost burden associated with SCLC varies across different patient subpopulations, where data allowed. The following subpopulations were examined when analysing the results: smokers and non-smokers; programmed death-ligand 1 (PD-L1) positive and PD-L1 negative; relapse/refractory disease (second-/third-line therapy) and non-advanced (first-line therapy) SCLC; limited- and extensive-stage disease; and brain metastases associated with SCLC. A further exploratory objective investigated in the SLR was the potential to distinguish between 'disease symptom burden' and 'treatment burden'.

A literature search was conducted to identify publications relating to the costs of SCLC. The following computerised bibliographic databases were searched using the OVID search engine for the economic burden SLR: PUBMED (MEDLINE), MEDLINE^®^ In-Process, EMBASE, EconLIT and National Health Service economic evaluation database (NHS EED). The search was limited to studies published in the past 10 years (1 January 2005--24 February 2016) and excluded preclinical studies. To ensure all publications of interest were captured, both English and non-English language publications were included in the search. The search utilised a combination of disease and cost burden subject headings and free-text searching in order to ensure that the most relevant literature was identified and reviewed (see [Appendix A](#Sec16){ref-type="sec"}).

All abstracts identified in the search were screened for full-publication review by two independent reviewers (MP and RW). Any disagreement was resolved by a third senior researcher (AE). Publications reporting costs associated with patients without specific reference to SCLC, or reporting data on treatment efficacy/interventional data in SCLC, which did not assess the economic burden, were excluded. Publications reporting data for patients \<16 years of age, study populations of \<30 patients, or publications consisting of letters, editorials or commentaries, as well as publications with no study length restrictions, were also excluded.

Publications were included in the full-text review based on the following inclusion criteria: publications presenting data specific to or including SCLC patient populations in the following geographical regions: Australia, Brazil, Canada, Europe, Japan, Russia or the US; publications reporting the direct or indirect costs associated with the management of SCLC across these countries and regions; and publications presenting data specific to or including patients with SCLC.

All included publications were assessed for quality against an adapted version of the DRUMMOND checklist \[[@CR9]\]. Some publications identified through the primary search were abstracts and posters, therefore a full quality assessment was not possible.

As recommended by the Cochrane Collaboration \[[@CR10]\], when studies provided sufficient methodological information, cost data were converted to a common currency and year (2016 US\$) using a cost converter tool provided by the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Co-ordinating Centre (see [Appendix B](#Sec17){ref-type="sec"}) \[[@CR11]\].

An additional internet-based search was conducted to identify any further relevant literature. This internet-based search was conducted using a combination of keywords and included both non-peer-reviewed publically available information and peer-reviewed publications that may not yet be indexed in databases such as PUBMED or Embase, because of their recent publication date, or because they were published in journals that are not indexed within these databases. Conference proceedings from the annual European, US, Asia--Pacific and Latin American congresses of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the American Society of Clinical Oncology (ASCO) annual meeting, the annual European Cancer Congress (ECC), European Society for Medical Oncology (ESMO) and the annual World Conference on Lung Cancer (WCLC) were reviewed.

Results {#Sec3}
=======

A total of 229 publications were identified: 217 in the OVID search and 12 in the additional internet-based search. As the search retrieved only a small number of publications, indicating a paucity of primary studies on the cost burden of SCLC, it was decided that the review should also capture secondary evidence such as economic modelling studies, if these presented evidence on the costs of the disease. Primary references within existing systematic reviews were also examined to identify further relevant data, even if these primary sources were not captured directly by this search.

Following abstract screening and full-text review, a total of 12 full-text publications from the OVID search \[[@CR12]--[@CR25]\] were taken forward for inclusion in the SLR (Fig. [1](#Fig1){ref-type="fig"}). OVID searching identified four conference abstracts and one poster that were relevant in the context of this review, however full-text publications could not be sourced \[[@CR26]--[@CR28]\]. These publications will be referred to as 'grey literature' throughout this manuscript. As there was a paucity of publications identified on the cost burden of SCLC, these grey literature sources were included in the final SLR, resulting in a total of 17 inclusions \[[@CR12]--[@CR28]\].Fig. 1PRISMA flow chart of the included and excluded publications. *PRISMA* Preferred reporting items for systematic reviews and meta-analyses

No further publications were retained from the search of internet-based sources (such as disease-specific and patient advocacy websites and conference proceedings from ISPOR, ASCO, ECC, ESMO and the WCLC), as the 12 conference abstracts identified did not provide data specific to SCLC and costs \[[@CR29]--[@CR40]\].

The number of publications identified and the type of publications included in the SLR are presented in Fig. [2](#Fig2){ref-type="fig"}. Three literature reviews were included in this review as they undertook economic evaluations of SCLC costs; however, the primary publications reported in these reviews did not report SCLC-specific costs and were therefore not included in the review \[[@CR15], [@CR19], [@CR21]\].Fig. 2PRISMA graph of the included publications, grouped by type of publication. *PRISMA* Preferred reporting items for systematic reviews and meta-analyses

The publications were grouped based on the costs reported in direct and indirect costs.

The majority of publications reported on direct costs (*n* = 16) and only one publication reported on both direct and indirect costs (*n* = 1). Further details of publications included within the SLR are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of publications included in the SLRAuthorsYearType of studyCountryObjectiveNSCLCStage of SCLC reportedSubgroup of interest reported*Direct costs*Cakir et al. \[[@CR12]\]2007Prospective observational studyTurkeyTo evaluate the individual and societal burden of lung cancer in TurkeyReportedMixed^b^Not reportedDecroisette et al. \[[@CR25]\]2011Prospective observational studyFranceTo document the epidemiology, management, and bone metastatic disease treatment costs of patients with lung cancer with bone metastatic diseaseNot reportedExtensiveNot reportedDuh et al. \[[@CR13]\]2008Retrospective observational studyUSTo assess costs associated with intravenous (IV) chemotherapy in patients with SCLC from the perspective of large employer-payersNot reportedNot reportedNot reportedGrossi et al. \[[@CR14]\]2013Retrospective observational studyItalyTo evaluate the economic effect of clinical trials of new lung cancer treatments on the total pharmaceutical expenditure on these treatmentsReportedNot reportedNot reportedHartwell et al. \[[@CR15]\]2010Literature reviewUKTo assess the clinical and cost-effectiveness of topotecan within its licensed indications for patients with relapsed SCLC. This review discusses the possible implications of appraising this technology from the perspective of the United Kingdom (UK) healthcare systemNot reportedMixed^b^Second-line treatmentKang et al. \[[@CR16]\]2012Retrospective observational studyAustraliaTo describe the current pattern of resource use and direct medical costs associated with managing lung cancer in South Western Sydney, AustraliaReportedMixed^b^Not reportedKarve et al. \[[@CR17]\]2012Retrospective observational study^a^USTo provide a summary of trends in treatment patterns and direct healthcare costs among elderly Medicare patients diagnosed with and receiving cancer-directed treatment for distant stage SCLC and NSCLCReportedNot reportedNot reportedKuwabara et al. \[[@CR18]\]2009Retrospective observational studyJapanTo investigate the differences in practice between SCLC and NSCLC patients and examine how lung cancer-related severity, such as pathological diagnosis or cancer staging, impacts on costsReportedMixed^b^Not reportedLouie et al. \[[@CR22]\]2015ModelUSTo evaluate the clinical benefits and cost-effectiveness of prophylactic cranial irradiation (PCI) with hippocampal avoidance (HA) for limited stage SCLC patientsNot reportedLimitedBrain metastasesLoveman et al. \[[@CR19]\]2010Literature reviewUKTo assess the clinical effectiveness and cost-effectiveness of topotecan as a second-line treatment for SCLC. This health technology assessment document discusses the possible implications of appraising this technology from the perspective of the UK healthcare systemNot reportedMixed^b^Brain metastasesPatrice et al. \[[@CR26]\]2015ModelUSTo evaluated the cost-effectiveness of adding thoracic radiation therapy to chemotherapy and PCI in extensive stage SCLC patientsNot reportedExtensiveSecond-line treatmentPertile et al. \[[@CR20]\]2015Prospective observational studyItalyTo estimate the cost-effectiveness of the PREDICA (population-based cohort study of chest X-ray screening in smokers) screeningReportedNot reportedSmokers; first-line treatmentRuben and Ball \[[@CR21]\]2012Literature reviewAustraliaTo establish the efficacy of a positron emission tomography (PET)-based staging of SCLC compared to conventional methods, the potential impact on patient management and outcomes, and cost implications for the Australian health systemNot reportedMixed^b^First-line treatmentTan Sean et al. \[[@CR23]\]2009Retrospective observational studyFranceTo evaluate the economic implications of using pegfilgrastim versus granulocyte colony-stimulating factor (G-CSF) to prevent febrile aplasia induced by chemotherapy for SCLCNot reportedNot reportedNot reportedTimmer-Bonte et al. \[[@CR24]\]2008ModelNetherlandsTo use a Markov model to investigate the economic consequences of secondary prophylactic use of different prophylactic strategies (antibiotics, antibiotics plus G-CSF, and a combined sequential approach) in a population at risk of febrile neutropeniaReportedNot reportedFirst-line treatmentTurk et al. \[[@CR27]\]2015Retrospective observational studyTurkeyTo establish the direct costs of diagnosing lung cancer in hospitalised patients in TurkeyReportedMixed^b^Not reportedWeycker et al. \[[@CR28]\]2011ModelNot reported (abstract only)To use a model to investigate the consequences of a single screening of screening-naïve older adult smokers for lung cancer using an autoantibody test (AABT) versus computer tomography (CT) screeningReportedNot reportedSmokers; first-line treatment*Indirect costs*Cakir and Karlikaya \[[@CR12]\]2007Prospective observational studyTurkeyTo evaluate the individual and societal burden of lung cancer in TurkeyReportedMixed^b^Not reported*SLR* Systematic literature review, *CT* computed tomography, *G*-*CSF* granulocyte colony-stimulating factor, *SCLC* small cell lung cancer, *NSCLC* non-small cell lung cancer, *PCI* prophylactic cranial irradiation, *HA* hippocampal avoidance, *AABT* autoantibody test, *PET* positron emission tomography, *IV* intravenous^a^This is a longitudinal cohort study, years of data collected in the body of the report^b^Mixed SCLC is defined as limited- and extensive-stage SCLC reported in the same publication

Quality Assessment {#Sec4}
------------------

To assess the quality of all included publications, an adapted DRUMMOND checklist for economic evaluation quality assessment was used \[[@CR9]\]. The assessment included three aspects (study design, data collection, and analysis and interpretation of results) and a total of 36 criteria. Each publication was independently assessed for quality by two researchers and given a score of 0 = not reported, 1 = not clear, or 2 = reported (or NA if not applicable). Scores were then summed and a percentage given for each publication from the number of questions that were applicable to that publication.

For example, a publication may have information reported for five items (equating to 10 points), not reported for three items (=0 points), not clear for three items (=3 points) and not applicable for two items, totalling 13 points. In this case, the total number of applicable items (items that score 0, 1, or 2) is 11, and hence the total number of possible points is 22; therefore, the publication's final quality score is 59% \[(13÷22) × 100\].

The assessed publications received a high-quality score, ranging from 73.1 to 91.7% (see Table [2](#Tab2){ref-type="table"}). Four publications could not be assessed in this way as they were abstracts or posters only and therefore could not be scored \[[@CR22], [@CR26]--[@CR28]\]. However, due to the paucity of data retrieved from the primary search, these publications were included in the final SLR.Table 2Quality assessment of the included publications using the adapted DRUMMOND checklist \[[@CR9]\]PublicationTotal scoreNumber of applicable questionsTotal quality percentageCakir and Karlikaya \[[@CR12]\]211380.8Decroisette et al. \[[@CR25]\]191373.1Duh et al. \[[@CR13]\]221384.6Grossi et al. \[[@CR14]\]201283.3Hartwell et al. \[[@CR15]\]221291.7Kang et al. \[[@CR16]\]211380.8Karve et al. \[[@CR17]\]221384.6Kuwabara et al. \[[@CR18]\]201376.9Loveman et al. \[[@CR19]\]231388.5Ruben and Ball \[[@CR21]\]211380.8Timmer-Bonte et al. \[[@CR24]\]191373.1Pertile et al. \[[@CR20]\]211380.8Tan Sean et al. \[[@CR23]\]201376.9

Direct Costs {#Sec5}
------------

The direct costs of SCLC were reported in 17 studies. The research focus varied across publications and different cost items were reported, as described in Table [1](#Tab1){ref-type="table"}.

Direct cost components were chosen arbitrarily by the authors on the basis of their respective objective, and could not be compared. This was indicative of the paucity of data found on SCLC costs and the varied nature of how they were reported. Several direct cost components were identified as potential cost drivers for the economic burden of SCLC. Chemotherapy and associated costs were identified as major cost components in five publications \[[@CR12]--[@CR14], [@CR16], [@CR26]\]. Diagnostic costs were high in SCLC, including costs of computed tomography, positron emission tomography (PET), chest x-ray, magnetic resonance imaging (MRI), cytohistology, bone scans and screening administration \[[@CR12], [@CR16], [@CR18], [@CR20], [@CR21], [@CR28]\]. Treatment costs represented a significant proportion of direct costs, specifically SCLC medication costs or surgical costs, which included high associated treatment costs, such as hospitalisation, nurse visits, emergency room visits, follow-up appointments, and inpatient and outpatient care \[[@CR12], [@CR16], [@CR17], [@CR20], [@CR23], [@CR25], [@CR27]\].

Several publications investigated cost components of lung cancer \[[@CR12], [@CR13], [@CR16], [@CR27]\]. In Turkey, the mean total cost per lung cancer patient was reported by Cakir and Karlikaya as \$14,306 (USD, cost year not specified), and the median total cost per patient was reported by Turk et al. as €910 (€, cost year not specified) \[[@CR12], [@CR27]\]. High costs were reported in treatment and inpatient services in Turkey, as well as direct medical costs (Table [3](#Tab3){ref-type="table"}) \[[@CR12]\]. Costs in the US were \$896.73 per chemotherapy visit or \$10,760.85 per course of treatment (Table [4](#Tab4){ref-type="table"}) \[[@CR13]\]. In Australia, the median cost per month of survival for all lung cancer (SCLC and NSCLC) patients was AU\$1854 (AU\$, review of patient records 2005--2008, applying 2005 Australian Medicare Benefits Schedule costings, adjusted to 2016 US\$) \[[@CR16]\]. Hospitalisation and chemotherapy were the highest direct costs reported (see Table [5](#Tab5){ref-type="table"}) \[[@CR16]\].Table 3The cost of lung cancer in Turkey (US\$, cost year not specified) \[[@CR12]\]Type of cost*N*TotalMean ± SDUpper and lower limitsDirect medical costs103^a^\$564,490\$5480 ± 4088\$316--24,574Additional medical costs10\$7755\$775 ± 1097\$3--3316Direct non-medical costs103^a^\$34,415\$334 ± 1324\$5--13,500Total direct costs103^a^\$606,660\$5890 ± 4186\$436--24,779Total cost of lung cancer103^a^\$1,473,530\$14,306 ± 17,705\$771--104,079*SD* Standard deviation^a^Five patients died during the study, therefore only 103 were included in the cost analyses Table 4Estimated costs per IV chemotherapy visit and course of treatment in SCLC (*n* = 802) in the US (US\$, 2007 costs adjusted to 2016 US\$) \[[@CR13]\]CategoryCost per visit (mean ± SD)Cost per course (mean ± SD)^a^% of totalIV chemotherapy drugs^b^\$450.01 ± 786\$5400.15 ± 944250.2IV chemotherapy administration procedures\$105.56 ± 136\$1266.71 ± 164611.8Other visit-related drugs and services^c^\$341.16 ± 802\$4094.01 ± 963538.0Total cost\$896.73 ± 1352\$10,760.85 ± 16,242100.0*IV* Intravenous, *SD* standard deviation, *SCLC* small cell lung cancer^a^A course of IV chemotherapy is assumed to include 12 visits (3 visits per cycle × 4 cycles)^b^Drugs included cisplatin, etoposide, irinotecan, carboplatin, topotecan, and CAV (cyclophosphamide/adriamycin/vincristine)^c^Other visit-related drugs and services included chemotherapy assessments, erythropoietic agents, evaluation and management, laboratory services, other IV drugs, other IV administration procedures, other medical services, radiology, saline, serotonin antagonists, supplies/durable medical equipment, and surgical procedures Table 5Total and mean treatment costs by stage and modality (AU\$, review of patient records 2005--2008, applying 2005 Australian Medicare Benefits Schedule costings, adjusted to 2016 US\$) \[[@CR16]\]*N*Surgery (%)Radiotherapy (%)Chemotherapy (%)Hospitalisation (%)Total costMean costSCLC Limited-stage8\$0 (0)\$47,991 (39)\$29,482 (24)44,787 (37)\$122,260\$19,046 Extensive-stage21\$1416 (1)\$15,940 (8)\$43,147 (22)\$138,510 (69)\$199,013\$12,688Total (NSCLC and SCLC cohort)210\$73,577\$420,708\$599,904\$1,162,494*SCLC* Small cell lung cancer, *NSCLC* non-small cell lung cancer

Chemotherapy costs were also a major component of lung cancer costs \[[@CR12], [@CR27]\]. Intravenous chemotherapy administration and other visit-related drugs and services accounted for nearly half of the total cost per intravenous visit day in one study \[[@CR13]\]. A substantial economic burden on patients with extensive-stage SCLC and NSCLC was observed in the US (see Table [6](#Tab6){ref-type="table"}) \[[@CR17]\]. The primary drivers of costs were hospitalisation, office visits, and hospital outpatient visits, and chemotherapy use was significantly more prevalent in SCLC compared with NSCLC \[[@CR17]\].Table 6Mean total healthcare costs per patient in the US (US\$, cost year not specified) \[[@CR17]\]All-cause^a^Lung-cancer-relatedSCLCNSCLC*p*-ValueSCLCNSCLC*p*-ValueHospitalisations\$32,456\$32,0270.403\$12,498\$9778\<0.001Office visits\$22,340\$18,027\<0.001\$19,168\$15,822\<0.001Hospital outpatient visits\$7253\$70400.270\$6044\$57670.116Hospice\$3099\$3693\<0.001\$2933\$3419\<0.001Other ancillary care\$2624\$25020.086\$1656\$14950.001Skilled nursing facility\$2453\$26070.111\$1790\$17750.846ER visits\$324\$3120.022\$78\$760.389Total costs\$70,548\$67,175\<0.001\$44,167\$37,932\<0.001*SCLC* Small cell lung cancer, *NSCLC* non-small cell lung cancer, *ER* emergency room^a^Lung cancer- and non-lung cancer-related healthcare costs

In Italy, the economic impact of patients enrolling in sponsored clinical trials on national healthcare spending was examined \[[@CR14]\]. The costs of chemotherapy agents were reported to be high and the enrolment of 44 patients in sponsored clinical trials produced a saving of 30% of the pharmaceutical expenses for antineoplastic agents, however no specific cost data were reported \[[@CR14]\].

In Japan, median hospital length of stay was longer for SCLC (20 days) than NSCLC (18 days) patients, and total charges (US\$, cost year not specified) differed significantly between SCLC (\$6015) and NSCLC patients (\$6993) \[[@CR18]\]. A review investigated PET-based staging for SCLC in Australia, reporting its cost to be AU\$1189.10 per patient, compared with conventional staging costs of AU\$1194.29 (2010 Australian Medicare Benefits Schedule costings, adjusted to 2016 US\$) \[[@CR21]\]. The costs of SCLC and NSCLC management were investigated in Australia, where the costs of managing NSCLC and SCLC were found to be comparable \[[@CR16]\].

### Direct Costs of Limited- and Extensive-Stage Small Cell Lung Cancer (SCLC) {#Sec6}

Several publications reported on direct costs of extensive-stage SCLC specifically \[[@CR12], [@CR15]--[@CR19], [@CR21], [@CR22], [@CR25], [@CR27]\]. Kang et al. investigated the costs of SCLC management and found that the median cost of lung cancer in Australia was highest for limited-stage SCLC (\$19,046 vs. \$12,688 for extensive-stage) \[AU\$, review of patient records 2005--2008, applying 2005 Australian Medicare Benefits Schedule costings, adjusted to 2016 US\$\]. Patients with extensive-stage SCLC had the highest proportion of their management costs spent on hospitalisation (see Table [5](#Tab5){ref-type="table"}) \[[@CR16]\].

Turk et al. examined the diagnosis costs of SCLC patients hospitalised in Turkey (€, cost year not specified) and reported the total cost of diagnosis per patient as €937 in limited-stage SCLC and €502 in extensive-stage SCLC \[[@CR27]\]. Furthermore, Patrice et al. found that the addition of thoracic radiation therapy to prophylactic cranial irradiation (PCI) in extensive-stage SCLC patients in the US resulted in a \$4066 cost increase (US\$, cost year not specified) \[[@CR26]\].

Karve et al. reported on healthcare costs per patient for extensive-stage SCLC and metastatic NSCLC in the US (US\$, cost year not specified). In both the SCLC and NSCLC cohorts, hospitalisation was the predominant cost driver, accounting for approximately half of all costs (see Table [6](#Tab6){ref-type="table"}). SCLC disease-related costs were a larger percentage of total (all-cause) costs compared with NSCLC (62.6% vs. 56.4%) \[[@CR17]\].

Seven other publications reported on extensive- and limited-stage SCLC, however the costs reported were not separated by extensive and limited SCLC \[[@CR12], [@CR15], [@CR18], [@CR19], [@CR21], [@CR22], [@CR25]\].

### Direct Costs of Prophylactic Therapies {#Sec7}

Prophylactic therapy costs were reported frequently, with two modelling and one observational publication reporting on the direct costs of multiple prophylactic therapies, or presenting mean costs of prophylactic therapy \[[@CR22]--[@CR24]\]. Timmer-Bonte et al. investigated the economic burden of secondary prophylactic use of different prophylactic strategies in extensive-stage SCLC patients at risk of febrile neutropenia in The Netherlands and found that the most expensive strategy was antibiotics plus granulocyte colony-stimulating factor (G-CSF), with a mean cost of \$13,338 per patient (converted from 2002 € to 2016 US\$; original cost year derived from a further publication on the same study, cited within the captured publication) \[[@CR41]\] (Table [7](#Tab7){ref-type="table"}). The relatively high price of administering G-CSF was the determining cost factor \[[@CR24]\].Table 7Cost per patient per secondary prophylactic strategy in baseline model (US\$, converted from 2002 € to 2016 US\$) \[[@CR24]\]Patient groupBootstrap^a^Mean per patient95% CIAntibiotics\$6660\$5387--8052Antibiotics plus G-CSF\$13,328\$11,269--15,504Primary antibiotics, secondary G-CSF\$8843\$7209--10,745*CI* Confidence interval, *G*-*CSF* granulocyte colony-stimulating factor^a^In bootstrap analysis, the original cost data sample was parameterised normally by bootstrapping the original sample

In France, the economic implications of using pegfilgrastim to prevent febrile neutropenia induced by chemotherapy in SCLC were explored \[[@CR23]\]. The difference in the costs of preventing and managing febrile neutropenia between the two strategies was €1743 for the pegfilgrastim strategy and €1466 for the G-CSF strategy (€, cost years not consistently reported). Pegfilgrastim was more costly than first-generation G-CSF; however, concern about the excess cost may be reduced by the perceived convenience of the pegfilgrastim strategy \[[@CR23]\].

The cost of PCI with hippocampal avoidance was reported as \$13,377.61 versus \$6388.28 for PCI in limited-stage SCLC patients in the US (Medicare's 2014 reimbursement rate adjusted to 2016 US\$) \[[@CR22]\].

### Direct Costs of Bone Metastatic Disease {#Sec8}

As part of the secondary objectives of this SLR, the costs of bone metastasis were investigated. A French prospective, observational study reported on bone metastasis in SCLC \[[@CR25]\]. The total cost of bone metastatic disease for both SCLC and NSCLC was €1,715,213 (cost year not specified) for the entire cohort of patients (*n* = 554) \[[@CR25]\]. The mean management cost during the first year after onset was €3999, of which 49.5% was linked to the management of patients with skeletal-related events. Metastatic bone disease presented a significant driver of oncology costs, with skeletal-related events being the most burdensome cost of bone metastatic disease management \[[@CR25]\].

### Cost of SCLC by Subpopulations {#Sec9}

The economic burden of disease in different SCLC subgroups was also explored in this review. Due to the diverse study designs of publications presenting smoking and non-smoking populations, comparisons could not be made on any variation in cost between these subpopulations.

The costs of SCLC staging were investigated in two publications, with Kang et al. presenting cost differences between each stage of SCLC in Australia \[[@CR16]\], while Karve et al. reported on the most used first-, second- and third-line treatments in extensive SCLC in US \[[@CR17]\]. Kang et al. reported that the median total cost increased along with progressing stage for NSCLC and SCLC, with the median total cost for limited SCLC reported as AU\$20,826, and AU\$13,874 for extensive-stage SCLC (AU\$, review of patient records 2005--2008, applying 2005 Australian Medicare Benefits Schedule costings, adjusted to 2016 US\$). The median cost per patient was highest for limited-stage SCLC (see Table [5](#Tab5){ref-type="table"}), while the median cost per month of survival for all lung cancer (SCLC and NSCLC) patients was AU\$1854 \[[@CR16]\]. Hospitalisation and chemotherapy were the greatest components of cost, representing 44 and 22% of total costs, respectively. Overall, the total costs of managing SCLC and NSCLC were comparable \[[@CR16]\].

Karve et al. also reported on high hospitalisation costs in both the extensive-stage SCLC and metastatic NSCLC cohorts, accounting for approximately half of all costs \[[@CR17]\]. Chemotherapy use was significantly more prevalent in extensive-stage SCLC compared with metastatic NSCLC, while surgery and radiation therapy were more prevalent in metastatic NSCLC. Utilisation of haematopoietic growth factors and some supportive care therapies were significantly higher in extensive-stage SCLC patients, however the authors did not explore the reasons for this \[[@CR17]\].

Two publications reported on patients with brain metastases but did not present separate costs for patients with these metastases, therefore no conclusions could be drawn \[[@CR19], [@CR22]\]. The lack of information on the costs of brain metastases in SCLC highlights this as a crucial area where more research is needed.

### Symptom Burden versus Treatment Burden {#Sec10}

Despite the systematic nature of this review, no publications were found that distinguished between symptom and treatment burden directly, therefore no conclusions could be drawn.

Indirect Costs {#Sec11}
--------------

Indirect SCLC costs, such as lost productivity (e.g. absenteeism), care costs (indirect costs associated with caring and house work), out-of-pocket expenses, income foregone due to illness-related early retirement, and presenteeism were investigated in this SLR. The i ndirect costs of SCLC were captured in a single publication by Cakir and Karlikaya and included lost productivity due to premature death (total \$866,870; US\$, cost data not specified; 59% of total lung cancer costs) \[[@CR12]\]. This study found that the indirect costs experienced by patients in Turkey varied widely, ranging from \$500 to \$99,000 \[[@CR12]\]. Indirect costs were high in relation to the total costs presented, however these costs were not compared with indirect costs of other cancers \[[@CR12]\]. Work productivity was the only indirect cost component reported for SCLC patients, highlighting the need for more studies in this area.

Discussion and Conclusions {#Sec12}
==========================

The publications included within this SLR varied widely in methodology, patient characteristics (e.g. age, proportion of male patients, cancer stage), analytical methods, type of reported costs (costs associated with, for example, diagnosis, surgery, treatment), and cost components (e.g. inpatient costs, outpatient costs, administration). Publications also varied by region of interest, including studies conducted in Europe \[[@CR12], [@CR14], [@CR15], [@CR19], [@CR20], [@CR23]--[@CR25], [@CR27]\], North America \[[@CR13], [@CR17], [@CR22], [@CR26]\], Oceania \[[@CR16], [@CR21]\], and Asia \[[@CR18]\].

The majority of identified publications were observational studies (*n* = 10), followed by modelling studies (*n* = 4) and SLRs (*n* = 3). Most publications (9/17) reported data for both SCLC and NSCLC patients, while only eight studies reported on SCLC patients only \[[@CR13], [@CR15], [@CR19], [@CR21]--[@CR23], [@CR25], [@CR26]\]. Generally, SCLC patients were the minority of lung cancer patients, while NSCLC patients were the majority, results that are aligned with the general population of lung cancer patients \[[@CR42]\]. To the authors' knowledge, this is the first SLR of the economic burden of SCLC and the results summarised here will contribute significantly to the understanding of the true magnitude of costs associated with SCLC. The varied nature of the studies captured indicates the need for a uniform and consistent approach when reporting on costs of SCLC, as well as a clear need for more research in this field.

It must be noted that the authors of the identified publications based the reported costs (e.g. costs associated with diagnosis, surgery, treatment, hospitalisation) on different sources, such as published literature, databases, operative unit reviews and individual hospital data. They also used different currencies, and the cost components (e.g. inpatient costs, outpatient costs, administration) contributing to reported total costs varied widely and were chosen arbitrarily by the authors of the identified publications, in accordance with the research questions the research was trying to address. To this end, the data included in this review are very heterogeneous in type and magnitude, making direct comparison and conclusions challenging.

In comparison to a systematic review previously conducted on NSCLC, there were very limited data on the indirect costs of SCLC \[[@CR43]\]. The only indirect costs of SCLC captured were lost productivity due to premature death \[[@CR12]\]. The most commonly reported indirect cost in NSCLC was lost productivity, along with caregiver burden, although only five papers reported on indirect costs in that review \[[@CR43]\]. As information on indirect costs of SCLC was scarce in the peer-reviewed literature, grey literature sources were identified to augment the findings of the SLR. Increased caregiver work and activity impairment in lung cancer were reported in conference proceedings \[[@CR29]\], and a high economic burden of lung cancer illness was also reported \[[@CR39]\]; however, none of these additional findings investigated SCLC directly, providing only limited information for this literature review.

Direct costs, including drug costs and cost of hospital admissions, were the most commonly reported costs for both NSCLC and SCLC (*n* = 17). Many publications included in this SLR reported on general lung cancer costs that included SCLC (9/17), but the proportion of SCLC patients was not always reported, creating uncertainty about the relevance of the data. Due to the heterogeneity and limited availability of the economic burden of SCLC data, the results from this systematic review and grey literature search have been presented as a narrative synthesis, without any direct comparisons made.

A secondary objective of the SLR was to identify whether any differences exist between patient subpopulations. The following patient subpopulations were reported in the publications included within this review: smokers and non-smokers \[[@CR20], [@CR28]\], SCLC-stage costs \[[@CR16], [@CR17]\] and brain metastases \[[@CR19], [@CR22]\], and SCLC versus NSCLC \[[@CR16]--[@CR18], [@CR27]\]. However, due to the heterogeneity of costs reported, no conclusive evidence for how costs vary between these subpopulations could be provided. The SLR found no published data on the PD-L1 subgroup in SCLC. While PD-L1 expression strongly correlates with benefit for patients with NSCLC, there is a lower prevalence of PD-L1 expression in SCLC, which is likely the reason for the paucity of data found in this SLR \[[@CR44]--[@CR46]\]. A larger population analysis is required to establish whether PD-L1 expression correlates with benefits in SCLC \[[@CR44]\].

Limitations {#Sec13}
-----------

Certain limitations were noted during the course of this SLR. The broad research question of the SLR resulted in the identification of publications reporting a disparity of cost aspects related to SCLC disease diagnosis and management. Differences in study design, study objective and methodology increased heterogeneity in data reporting, and, as a result, no quantitative analysis, such as a meta-analysis, could be performed.

Additionally, only a minority of the studies provided sufficient information to allow their cost results to be converted to a fixed price-year, as is recommended by the Cochrane Collaboration \[[@CR10]\]. The majority of studies providing relevant cost data were not eligible for conversion: six studies stated when resource use had been captured, but failed to provide the year of costing information \[[@CR12], [@CR17], [@CR18], [@CR23], [@CR25], [@CR27]\], and one provided neither of these \[[@CR26]\]. This limitation identified within the captured studies therefore extends to this review, increasing the difficulty of comparing between studies.

The time horizon of the literature search was 10 years and publications reporting on cost analyses performed in 2005 or after were included. However, it is important to note that some of these publications include patient or disease management data collated prior to 2005. Whether data presented in this report can be extrapolated to the wider SCLC patient population in Australia, Brazil, Canada, Europe, Japan, Russia and the US would require further research.

A key step of the systematic review process is to ensure all publications included within the final analysis and reports are assessed for quality. In light of this, each publication was assessed for quality against an adapted version of the DRUMMOND checklist, which has been developed for the purpose of assessing the quality of economic evaluations \[[@CR9]\]. This checklist was used as it was perceived as being the only published quality control guidance applicable to the objectives of this review; however, it was not directly relevant to all publications reviewed. In this capacity, the DRUMMOND checklist was of limited application to some publications reviewed (some publications were abstracts or posters and presented limited information, i.e. no full justification of the methods etc., and some checklist questions were specific to modelling studies and were therefore not applicable to all types of publications).

Several non-peer-reviewed publications were included in this review as grey literature with the aim of augmenting the findings of this SLR, particularly with regard to the economic burden, which could have limited validity \[[@CR17], [@CR22], [@CR26]--[@CR28]\]. In addition to this, the inclusion of secondary sources, such as economic models and literature reviews, within this review may reduce its validity \[[@CR47]\].

Summary of Results {#Sec14}
------------------

In conclusion, the publications included within this review assessed the economic burden and/or indirect and direct costs of SCLC in Australia, Brazil, Canada, Europe, Japan, Russia and the US. Generally, there was a paucity of publications identified in this review reporting on economic burden and indirect costs, indicating a severe lack of research in this area. SCLC accounts for approximately 15% of all lung cancers, however few publications report on its economic burden compared with NSCLC \[[@CR4], [@CR43]\]. When reported, economic burden and indirect costs were high in relation to the total costs presented \[[@CR12]\]. Despite the direct costs being reported in numerous publications identified within this review, the costs reported were diverse, ranging from costs of diagnosis to costs for specific treatments and cost comparison analyses \[[@CR27]\]. In addition, the way in which costs were evaluated/analysed and reported varied, making direct comparisons difficult to conduct. Although diverse, all direct cost publications reported high direct costs in the context of the total costs associated with SCLC.

This review found that only a limited number of publications provided sufficient context for costs to be converted, and reinforces the finding that the available cost data in SCLC are diverse, both in magnitude and the treatments or resources for which they are available. Further research into the cost of SCLC is recommended, along with improved reporting to allow comparability.

Appendix A {#Sec16}
==========

See Table [8](#Tab8){ref-type="table"}.Table 8Total number of 'hits' for each stage of the economic burden of the SCLC searchSearch termsResultsSCLC or small cell lung carcinoma/or carcinoma, small cell/or small cell lung cancer/or small-cell lung cancer/or small cell carcinoma/or small-cell carcinoma/or small cell undifferentiated carcinoma/or small-cell undifferentiated carcinoma/or oat cell carcinoma/or oat-cell carcinoma/or combined cell carcinoma/36,387AND Healthcare cost/or economic burden/or economic impact/or social cost/or caregiver/or sick leave/or health expenditures/or hospital economics/or healthcare financing/or pharmaceutical fees/or medical fees/or hospital charges/or job performance/or work disability/or medical leave/or sickness benefit/or absenteeism/or productivity/or medical leave/or employer health costs/or sick leave/or employment/or informal care/or caregiver/or carer/or work impairment/or premature mortality/or life years lost/or \*morbidity/or economic aspect or financial aspect or cost of care or opportunity cost\* or drug cost\* or medical cost\* or service cost\* or supply cost\* or administrative cost\* or physician cost\* or nurse cost\* or infusion cost\* or administration cost\* or cost\* or \*hospitali\$ation/1,704,397Total458Limited to human/humans422Limited to year 2005--current236Total (duplicates removed)217*SCLC* Small cell lung cancer

Appendix B {#Sec17}
==========

See Table [9](#Tab9){ref-type="table"}.Table 9Cost data conversion for the included publicationsStudy name (location)Cost presented/reason for no cost conversionCost reportedCost year and currencyCorresponding 2016 US\$ valueCakir and Karlikaya (Turkey) \[[@CR12]\]Cost year not reported in the publication, therefore no cost conversion could be doneDecroisette et al. (France) \[[@CR25]\]Cost data not reported in the publication, therefore no cost conversion could be doneDuh et al. (US) \[[@CR13]\]Cost per chemotherapy visit11832007 US\$1347.24Cost per course of treatment14,19616,166.93Grossi et al. (Italy) \[[@CR14]\]Cost data not reported in this review, therefore no cost conversion was doneHartwell et al. (UK) \[[@CR15]\]Cost data not reported in this review, therefore no cost conversion was doneKang et al. (Australia) \[[@CR16]\]Median cost per patient of limited-stage disease20,8262005 AU\$19046.12Median cost per patient of extensive-stage disease13,87412688.27Karve et al. (US) \[[@CR17]\]Cost year not reported in publication, therefore no cost conversion could be doneKuwabara et al. (Japan) \[[@CR18]\]Cost year not reported in publication, therefore no cost conversion could be doneLouie et al. (US) \[[@CR22]\]Prophylactic cranial irradiation with hippocampal avoidance13,116.342014 US\$13,377.61Prophylactic cranial irradiation6263.516388.28Loveman et al. (UK) \[[@CR19]\]Cost data not reported in this review, therefore no cost conversion was donePatrice et al. (US) \[[@CR26]\]Cost data not reported in publication, therefore no cost conversion could be donePertile et al. (Italy) \[[@CR20]\]Cost data not reported in this review, therefore no cost conversion was doneRuben and Ball (Australia) \[[@CR21]\]PET-based staging16032010 AU\$1189.10Conventional staging16101194.29Tan Sean et al. (France) \[[@CR23]\]Cost year for the data included in this review not reported in publication, therefore no cost conversion could be doneTimmer-Bonte et al. (Netherlands) \[[@CR24]\]Antibiotics in prophylaxis of febrile neutropenia44962002 €6659.75G-CSF in prophylaxis of febrile neutropenia899813,328.39Primary antibiotics, secondary G-CSF in prophylaxis of febrile neutropenia59708843.13Turk et al. (Turkey) \[[@CR27]\]Cost year not reported in publication, therefore no cost conversion could be doneWeycker et al. (not reported) \[[@CR28]\]Cost data not reported in this review therefore, no cost conversion was done*PET* Positron emission tomography, *G*-*CSF* granulocyte colony-stimulating factor
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